STOCK TITAN
  1. Home
  2. Sec-filings
  3. MPLT
  4. [Form 4] MapLight Therapeutics, Inc. Insider Trading Activity

MapLight Therapeutics (MPLT) CAO and interim CFO reports 36,979-share stock sale

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. executive Jonathan Gillis, CAO and Interim CFO, reported selling 36,979 shares of Voting Common Stock from July 15–17, 2026 in seven Code S transactions at weighted-average prices ranging from $35.68 to $38.37 per share.

Certain July 15–16 sales are described as mandated “sell to cover” trades to satisfy statutory tax withholding obligations upon restricted stock unit vesting, while the July 17 sales were executed under a Rule 10b5-1 trading plan adopted on December 26, 2025. After one July 17 sale, the table shows 144,240 shares held directly.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider GILLIS JONATHAN
Role CAO and Interim CFO
Sold 36,979 shs ($1.37M)
Type Security Shares Price Value
Sale Voting Common Stock F6, F7 600 $36.51 $22K
Sale Voting Common Stock F6, F8 16,969 $37.61 $638K
Sale Voting Common Stock F6, F9 900 $38.17 $34K
Sale Voting Common Stock F1, F4 6,979 $36.66 $256K
Sale Voting Common Stock F1, F5 1,476 $37.44 $55K
Sale Voting Common Stock F1, F2 5,356 $36.13 $194K
Sale Voting Common Stock F1, F3 4,699 $36.94 $174K
Holdings After Transaction: Voting Common Stock — 144,240 shares (Direct)
Footnotes (9)
  1. F1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.68 to $36.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.68 to $37.325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.12 to $37.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.26 to $37.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. F6. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.
  7. F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.91 to $36.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  9. F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Shares sold 36,979 shares Aggregate Voting Common Stock sales reported for July 15–17, 2026
Sale price range $35.68–$38.37 per share Weighted-average sale price ranges described in transaction footnotes
10b5-1 plan adoption date December 26, 2025 Date Jonathan Gillis adopted the Rule 10b5-1 trading plan used for July 17, 2026 sales
Direct holdings after one sale 144,240 shares Direct Voting Common Stock reported as held after one July 17, 2026 transaction
Number of sale transactions 7 Total Code S non-derivative transactions reported for July 15–17, 2026
Rule 10b5-1 trading plan regulatory
"This transaction was made pursuant to a <b>Rule 10b5-1 trading plan</b> adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"tax withholding obligations in connection with the vesting of the <b>restricted stock units</b>"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
statutory tax withholding obligations financial
"shares required to be sold to cover the <b>statutory tax withholding obligations</b> in connection with the vesting"
weighted average price financial
"The price reported in Column 4 is a <b>weighted average price</b>. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider activity did MapLight Therapeutics (MPLT) report for Jonathan Gillis?
MapLight Therapeutics reported that CAO and Interim CFO Jonathan Gillis sold 36,979 shares of Voting Common Stock over July 15–17, 2026, across seven transactions, at weighted-average sale prices generally in the mid‑$30s per share.

How many MapLight Therapeutics (MPLT) shares did Jonathan Gillis sell and at what prices?
Jonathan Gillis sold a total of 36,979 shares of MapLight Therapeutics Voting Common Stock at weighted-average prices ranging from about $35.68 to $38.37 per share, according to the detailed transaction and footnote disclosures.

Were Jonathan Gillis’s MapLight Therapeutics (MPLT) stock sales under a Rule 10b5-1 plan?
Yes. Several July 17, 2026 sales were made pursuant to a Rule 10b5-1 trading plan adopted by Jonathan Gillis on December 26, 2025, as described in the transaction footnotes accompanying the reported Form 4 entries.

Did any MapLight Therapeutics (MPLT) insider sales relate to tax withholding?
Yes. Footnotes state that certain July 15–16, 2026 sales by Jonathan Gillis represented shares sold to cover statutory tax withholding obligations arising from the vesting of restricted stock units, and were characterized as mandated “sell to cover” transactions.

How many MapLight Therapeutics (MPLT) shares did Jonathan Gillis hold after the reported trades?
Following one of the July 17, 2026 sales, the Form 4 table shows Jonathan Gillis directly holding 144,240 shares of MapLight Therapeutics Voting Common Stock, reflecting his updated ownership after that specific transaction entry.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GILLIS JONATHAN
(Last)(First)(Middle)
C/O MAPLIGHT THERAPEUTICS, INC.
800 CHESAPEAKE DRIVE
(Street)
REDWOOD CITY CALIFORNIA 94063
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CAO and Interim CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Voting Common Stock07/15/2026S(1)5,356(1)D$36.13(2)175,863D
Voting Common Stock07/15/2026S(1)4,699(1)D$36.94(3)171,164D
Voting Common Stock07/16/2026S(1)6,979(1)D$36.66(4)164,185D
Voting Common Stock07/16/2026S(1)1,476(1)D$37.44(5)162,709D
Voting Common Stock07/17/2026S(6)600(6)D$36.51(7)162,109D
Voting Common Stock07/17/2026S(6)16,969(6)D$37.61(8)145,140D
Voting Common Stock07/17/2026S(6)900(6)D$38.17(9)144,240D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.68 to $36.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.68 to $37.325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.12 to $37.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.26 to $37.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.91 to $36.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Kristopher L. Hanson, Attorney-in-Fact07/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR